ZomedicPharmaceuticals is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.pcgadvisory.com.

Download the PCG Zomedica Report

Learn More about Zomedica by gaining access to the latest Initiation report 

PCG REPORT

Your ticket to the latest on Zomedica

Our pets mean the world to us, and for 9 out of every 10 Americans, they are just as much a member of our family as our siblings, parents, and children. Because of our enduring love for them, we do our best to provide great medical care, and the veterinary industry earns an incredible $50 billion dollars a year as a result.

When our pets do get sick, Zomedica plans to step in with innovative solutions, cutting-edge products, and teams who love their animals as much as the rest of us.

Want to learn more about Zomedica’s future plans? Download the Research Report on Zomedica to get extensive value on key investor areas, including clinical research reporting results

Zomedica is an industry-leading development-stage company, with plans to deliver solutions through a diverse pipeline of diagnostics and for companion animal conditions.

Zomedica Aims to Fill Market Need for Treating Companion Animals 

Home to a robust pipeline of animal diagnostics focused on developing solutions for previously unmet needs 

With a market cap of under $60 million coupled with a robust pipeline and revenue potential in 2021, Zomedica is worthy of serious investor attention

Zomedica employs experienced doctors & veterinarians with decades of industry experience leading large cap companies.

The Market is Hungry for Unique Solutions- $10 Billion Dollars and growing

Zomedica has an unrivaled market opportunity within the $2.6B global companion animal diagnostics market with that expected to grow at a CAGR of nearly 10% through 2024 to $10B and beyond.

TRUFORMA™ is Zomedica’s flagship product that is expected to launch in the near term alongside a digital customer data platform which will connect the line of products and the company’s diagnostic pipeline. The digital data platform will support veterinary teams with clinically relevant business services, including inventory management and key performance metrics.

TRUFORMA™ is used to detect thyroid & adrenal disorders in dogs and cats in as little as 15 minutes.  It is comprised of a table-top instrument that uses disposable assay cartridges to test a range of samples including whole blood, serum, and plasma.  Feasibility data has been achieved & recently completed the verification of TRUFORMA™ and the first assay.

TRUFORMA™ is expected to deliver several milestones, inclusive of product launch in select target markets, international expansion of TRUFORMA, and the marketing of two first-ever point-of-care assays


Download the PCG Report on Zomedica to learn more about TRUFORMA™ and Zomedica’s go-to-market assays.

ZomedicPharmaceuticals is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.pcgadvisory.com.

DOWNLOAD

Driven by long-term and short-term growth

Zomedica is much like human diagnostic companies focusing on innovation, but unlike human pharmaceuticals have less red tape due to lesser FDA and governmental involvement which allows for shorter pipelines that are faster to market.

By focusing on an unmet need and creating real products backed by real data and validation of assays, Zomedica has a robust, diverse, and full pipeline that is ready to shake up an ever-growing industry.

Zomedica partnerships leverage relationships with Qorvo, Seraph Biosciences, and Celsee to advance products toward a global market opportunity.

Little to no pre-market regulatory for diagnostic platforms, allows for a faster moving pipeline

Diagnostics are the fastest growing sector in animal health with very few competitors

Near-term revenue potential with the launch of many validated products



Mr. Cohen is a seasoned medical device, pharmaceutical and biotechnology executive with a series of positions leading organizations with full P&L responsibility, and previous departmental management experience in virtually all functional areas, including international sales, R&D, healthcare services, M&A, corporate marketing, legal affairs and business & technology development, coupled with strategic oversight and planning positions.

About the CEO

Download the PCG Zomedica report

ZomedicPharmaceuticals is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures in the research report as well as on our website www.pcgadvisory.com.

Reasons to Consider Zomedica

DOWNLOAD

Watch the video